3,0
15 jun 2008
Voormalige werknemer
Ann Arbor, MI
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
Product Portfolio at one time was outstanding. Scale and ability to attract talented Scientists and Clinicians were also a benefit. Each research site was told that your ability to deliver on portfolio was critical to the site's viability.
Minpunten
Frequent site closures and lack of ability to focus on a single 'game plan' certainly dampened much of the enthusiasm & luck needed to deliver NDAs. The rate of in-licensing attrition was nearly as poor as development of 'in-house' candidates (many phase III pfailures). Retention of talented Scientists has also become more difficult as everyone counts the months until atorvastatin's patent expires.